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ABSTRACT
Objective: Renal disease complications in type 2 diabetes mellitus patients are characterized by progressive urinary albumin excretion and decreased 
glomerular filtration. The drugs most commonly prescribed as antidiabetic therapy in Indonesia are metformin and sulfonylurea. It is still unclear 
whether the effect of metformin-sulfonylurea on kidney is different from that of metformin monotherapy.
Methods: We compared the effectiveness of metformin monotherapy and metformin-sulfonylurea combination to the urine albumin-to-creatinine 
ratio (UACR) and estimated glomerular filtration rate (eGFR) as renal function parameters. Study subjects were patients on either of these drug 
regimens for at least 1 year. We collected 88 samples from type 2 diabetes mellitus patients (37 patients on metformin and 51 on metformin-
sulfonylurea). The patients fasted for 8 h before urine and blood collection for UACR and eGFR analysis. We measured the eGFR using the chronic 
kidney disease epidemiology collaboration (CKD-EPI) equation, serum creatinine, and urine creatinine by colorimetric enzymatic assay, and urine 
albumin by immunoturbidimetry.
Results: The eGFR level in the metformin and metformin-sulfonylurea groups was within the normal range, but lower in the metformin group 
(79.59±2.81) than in the metformin-sulfonylurea group (87.82±2.82) (p=0.018). In addition, hyperfiltration cases were more frequent in metformin-
sulfonylurea group (p=0.029). The UACR in patients taking metformin-sulfonylurea (177.95±60.92) was higher than that in the metformin group 
(49.58±14.19) but the difference between them was not significant (p=0.099).
Conclusion: Metformin monotherapy was associated with a lower frequency of hyperfiltration and lower UACR level compared to metformin-
sulfonylurea combination.
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INTRODUCTION
Diabetes mellitus is the leading cause of death among patients with end-
stage renal disease. Uncontrolled hyperglycemia in diabetic mellitus 
patients continuously exposes the body to high glucose levels. This 
condition triggers the development of complications in body organs, 
including the kidney [1]. In diabetes mellitus patients, renal disease 
complications are characterized by progressive urinary excretion 
through urine and a decreased glomerular filtration rate [2]. These 
patients are advised to have their kidney function monitored by urine 
albumin-to-creatinine ratio (UACR) and estimated glomerular filtration 
rate (eGFR) measurement. To prevent the progression of diabetic 
kidney disease, an early diagnosis is essential [3].
Glycemic control can prevent and delay the risk of diabetic 
nephropathy. In Indonesia, managing type 2 diabetes mellitus 
involves applying a healthy lifestyle (medical nutrition therapy and 
physical activity) and pharmacological therapy using antidiabetic 
medication. Antidiabetic medication may be given as a mono- or 
combination therapy. In primary health care, the most commonly 
used drug is metformin, either in monotherapy or in combination 
with sulfonylurea [4]. Previously, metformin use was contraindicated 
due to the susceptibility to lactic acidosis in type 2 diabetes mellitus 
patients with chronic kidney disease (CKD). In 2016, The U.S. Food 
and Drug Administration modified the recommendation of metformin 
use in patients with “mild to moderate renal dysfunction” (stage 1 
to 3a). Some studies showed that, apart from metformin’s capacity 
to treat type 2 diabetes, it is a potential nephroprotective agent [5]. 
However, to understand metformin’s nephroprotective nature, many 
experimental and clinical studies are still required [5]. It is reported 
that metformin-sulfonylurea combination has an antioxidant effect [6]. 
Conversely, metformin can reduce the risk of decreased renal function 
compared to a combination of metformin-sulfonylurea [7]. Meanwhile, 
another study found patients taking metformin-sulfonylurea to be 
at lower risk of kidney failure compared to those taking metformin 
[8]. Therefore, this study aimed to analyze UACR and eGFR as renal 
function parameters in patients taking metformin or a metformin-
sulfonylurea combination.
MATERIALS AND METHODS
We designed this study as cross-sectional with consecutive sampling. 
We obtained data from blood and urine sample analyses and other 
information from a validated questionnaire. We performed sampling at 
Pasar Minggu Community Health Center between March 2018 and May 
2018. We conducted the sample analyses at Prodia Laboratory, Depok, 
between March 2018 and May 2018. We recruited type 2 diabetes 
mellitus patients who were receiving treatment at Pasar Minggu 
Community Health Center and taking metformin or a metformin-
sulfonylurea combination for at least 1 year. Inclusion criteria were 
patient aged >18 years and fasting at least 8 h before sampling. 
Exclusion criteria were patient with severe anemia and hematuria. We 
registered this study in the Ethics Committee of Faculty of Medicine, 
University of Indonesia (No. 0163/UN2.F1/ETIK/2018). Before 
sampling, we received informed consent from patients and recorded 
their basic characteristics using a questionnaire.
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We instructed the patients to fast for at least 8 h before collecting urine 
and blood samples. We sampled urine by asking patients to collect 
30 mL of their first morning urine. Blood sampling was performed 
by a certified phlebotomist. We labeled the urine and blood samples, 
stored them in a cool box, and delivered them to Prodia Clinical 
Laboratory for UACR and eGFR analysis. Blood samples for HbA1c 
analysis were taken from the patients’ fingertips. HbA1c analysis 
was performed using AfinionTM AS100 analyzer (Alere, USA). We 
measured UACR by comparing urine albumin concentration with 
urine creatinine concentration. We measured urine albumin using the 
immunoturbidimetry principle and urine creatinine using the enzymatic 
colorimetric method. We converted the creatinine in the sample by a 
series of enzymatic reactions involving creatininase, creatinase, and 
sarcosine to form a peroxide that oxidizes 4-aminophenol, and then 
forms a color complex (quinone). The red absorbance, produced by 
quinone, at 545 nm is proportional to the creatinine concentration 
in the sample. We measured eGFR by determining serum creatinine 
with the enzymatic colorimetric method. We defined the eGFR’s value 
based on the CKD epidemiology collaboration (CKD-EPI) equation. We 
analyzed data using SPSS (IBM 2.0) software. We considered data to be 
significant if p<0.05.
RESULTS AND DISCUSSION
This study included 88 patients, 37 of whom were taking metformin, and 
the other 51 patients were taking metformin-sulfonylurea combination. 
We found no significant differences in any basic characteristics (Table 1). 
There were no differences in age and proportion of female and male 
samples in the two groups. The mean of body mass index in the two groups 
was included in moderate criteria (18.50–24.99 kg/m2). Body mass index 
can be affected by diet and exercise activities [9]. The proportions of 
patients consuming anti-hypertensive drugs and antihyperlipidemia 
drugs were also not significantly different (Table 1). The use of anti-
hypertension drugs is common in diabetic patients because diabetes and 
hypertension contribute along similar pathways such as the sympathetic 
nervous system, the renin-angiotensin-aldosterone system, oxidative 
stress, adipokines, insulin resistance, and PPARs [10]. These pathways 
interact and influence each other and may even cause a vicious cycle. 
Metabolic syndrome causes hypertension and diabetes [10]. Diabetic 
patients commonly have high cholesterol levels, especially those who 
cannot control their diets. To decrease the cholesterol levels, doctors often 
prescribe antihyperlipidemia drugs if lifestyle modification is inadequate.
Blood pressure, both systole and diastole, remained within the 
normal range in both groups. Urine creatinine level in patients taking 
a metformin-sulfonylurea combination was lower those in patients 
taking metformin but not significantly different (Table 2). However, 
urine creatinine level in both groups remained within the normal range. 
On the other hand, the urine albumin level in both groups exceeded the 
normal range. The urine albumin levels in patients taking a metformin-
sulfonylurea combination (177.95±60.92) were much higher than 
those in patients taking metformin (49.58±14.19), but not significantly 
different. Higher albumin levels in patients taking sulfonylurea were 
also reported by Hung et al. [7]. In their cohort of veterans with 
Table 1: Basic characteristics of study subjects
Characteristic Metformin (n=37) Metformin-sulfonylurea combination (n=51) p
Mean±SEM or n (%) Mean±SEM or n (%)
Age (years) 64.19±1.27 61.12±1.09 0.070b
Gender 
Female (n) 25 43 0.064a
Male (n) 12 8
Body mass index (kg/m2) 24.30±1.34 23.72±0.66 0.936c
Duration of diabetes (years) 7.21±0.86 8.95±0.81 0.155c
Exercise habit (n) 0.472a
Yes 24 (64.9) 28 (54.9) 
No 13 (35.1) 23 (45.1)
Smoking (n) 1.000a
Yes 0 (0.0) 1 (2.0)
No 37 (100.0) 50 (98.0)
Antihypertensive (n) 0.139a
Yes 15 (40.5) 30 (58.8) 
No 22 (59.5) 21 (41.2)
Antihyperlipidemia (n) 0.933a
Yes 9 (24.3) 14 (27.5) 
No 28 (75.7) 37 (72.5)
SEM: Standard error of mean; aChi-Square Test; bIndependent t-test; cMann-Whitney Test
Table 2: Clinical characteristics of study subject
Characteristic Metformin (n=37) Metformin-sulfonylurea combination (n=51) p
Mean±SEM or n (%) Mean±SEM or n (%)
Blood pressure
Systolic (mmHg) 125.14±2.59 122.94±1.99 0.501b
Diastolic (mmHg) 76.22±0.98 77.06±0.94 0.636 b
HbA1c (%) 7.75±0.22 9.04±0.25 0.001b*
Urine albumin (mg/L) 28.51± 6.45 105.72±39.06 0.315b
Urine creatinine (mg/dL) 81.93±11.20 65.11±5.81 0.559b
Serum creatinine (mg/dL) 0.87±0.04 0.76±0.03 0.006b*
UACR (mg/g) 49.58±14.19 177.95±60.92 0.099b
eGFR (mL/min/1.73 m2) 79.59±2.81 87.82±2.82 0.018b*
eGFR (n=86) 
eGFR≥90 mL/min/1.73 m2 13 (35.1) 30 (61.2) 0.029a*
eGFR<90 mL/min/1.73 m2 24 (64.9) 19 (38.8)
SEM: Standard error of mean. *Significant; aChi-square test; bMann-Whitney test
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type 2 diabetes, kidney function declined faster among initiators 
of sulfonylureas compared to metformin [7]. A lower risk of kidney 
function decline or death was associated with metformin initiation 
compared to sulfonylureas, independent of changes in body mass index, 
systolic blood pressure (SBP), and glycated hemoglobin over time [7].
In this study, we showed that glycated hemoglobin (HbA1c) levels in 
the metformin-sulfonylurea group were much higher compared to 
metformin (p=0.001) (Table 2). In both groups, the HbA1c level was 
more than 7% – still below the target for diabetes mellitus treatment 
(Table 2). HbA1c has a strong correlation with microalbuminuria 
development in patients with type 2 diabetes mellitus [11]. This means 
that the effectiveness of metformin and a metformin-sulfonylurea 
combination was still inadequate in this study, probably because 
patients do not comply with the prescribed dietary and lifestyle 
restrictions [12].
The serum creatinine level showed statistically significant differences 
in the two groups (p=0.006). However, the clinical serum creatinine 
level of these groups did not differ greatly and still within the normal 
range: 0.7–1.2 mg/dL for male and 0.5–0.9 mg/dL for female. There 
was no significant UACR difference (p=0.099) between groups. These 
results agree with a previous study [13]. The UACR in both groups was 
categorized as microalbuminuria in the 30–300 mg/g range. Although 
the difference was not statistically significant, the UACR in patients 
taking a metformin-sulfonylurea combination was higher than that in 
the metformin group. Kumar et al. (2019) reported that metformin 
monotherapy treatment (MMT) has shown a very good improvement 
in the progressive reductions in the levels of glycemic parameters (FPG, 
PPPG, and HbA1c) as well as maintaining the functions of kidney to 
near normal before and after 6 and 12 months of MMT [14].
Despite the potency of metformin monotherapy, this result may be 
influenced by high levels of HbA1c in the metformin-sulfonylurea 
combination patients. Glucose fluctuations may cause oxidant 
overproduction and endothelial dysfunction. In diabetic kidney disease 
pathogenesis, the overproduction of reactive oxygen species is the common 
mediator of several hyperglycemia-activated pathways [11]. Geetha et al. 
reported that there is a weak positive correlation of microalbuminuria 
with blood sugar levels, duration, and SBP [15]. If the microalbuminuria 
condition remains untreated, it can lead to further renal damage.
eGFR level in metformin group was lower than metformin-
sulfonylurea groups (p=0.018). Hyperfiltration, defined by eGFR 
≥90 mL/min/1.73 m2, was more frequent in metformin-sulfonylurea 
group, significantly (p=0.029). Renal function remained seems normal 
but was probably beginning to suffer damage [16]. eGFR elevation 
in patients taking a metformin-sulfonylurea combination does not 
indicate improved renal function over that of patients taking metformin. 
Rather, it indicates that patients taking a metformin-sulfonylurea 
combination with normal or elevated eGFR had begun to experience 
early renal impairment (CKD Stage 1 or 2), characterized primarily by 
microalbuminuria.
CONCLUSION
Metformin monotherapy was associated with a lower frequency 
of hyperfiltration and lower UACR level compared to metformin-
sulfonylurea combination.
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